Premium
Achyranthes bidentata polysaccharide suppresses osteoclastogenesis and bone resorption via inhibiting RANKL signaling
Author(s) -
Song Dezhi,
Cao Zhen,
Huang Song,
Tickner Jennifer,
Li Nan,
Qiu Heng,
Chen Xi,
Wang Chao,
Chen Kai,
Sun Youqiang,
Dong Shiwu,
Xu Jiake
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26682
Subject(s) - rankl , osteoclast , bone resorption , multinucleate , chemistry , resorption , microbiology and biotechnology , mapk/erk pathway , osteolysis , endocrinology , medicine , cancer research , signal transduction , biology , biochemistry , receptor , dentistry , activator (genetics)
Osteoclasts are highly differentiated multinucleated giant cells that play fundamental roles in bone resorption and in the pathogenesis of osteolytic conditions, such as osteoporosis and cancer‐induced bone loss. Achyranthes bidentata polysaccharide (ABP) is a hydrophilic compound with anti‐oxidation and anti‐aging characteristics. The impact of ABP on RANKL‐induced osteoclast formation and bone resorption has not been assessed, hence, in this study we investigated the effect of ABP on osteoclast formation and resorption in murine bone marrow derived osteoclasts. We found that ABP was able to suppress RANKL‐induced osteoclast differentiation and bone resorption activity at concentrations above 6.5 µM, while demonstrating no cytotoxicity at concentrations up to 10 µM. The actions of ABP were mediated through inhibition of RANKL‐induced c‐Fos and NFATc1 gene and protein expression. Furthermore, we found that ABP suppressed NFATc1 transcriptional activity, and the phosphorylation of MAPK pathways induced by RANKL. Collectively, ABP attenuates RANKL‐mediated osteoclast activity and signaling, and might serve as a potential therapeutic candidate for preventing bone loss related diseases.